Monash Ivf Group (ASX: MVF) — Company Overview, News & Financial Data
Monash IVF Group is a leading fertility services provider in Australia and Malaysia, focusing on compassionate patient care.
Monash Ivf Group
Monash Ivf Group is a healthcare company specializing in assisted reproductive technologies and tertiary-level prenatal diagnostics. The organization provides a comprehensive suite of fertility services, including in vitro fertilization, intracytoplasmic sperm injection, pre-implantation genetic testing, donor and surrogacy programs, and fertility preservation. It also delivers specialized diagnostic obstetric and gynaecological ultrasound services, genetic counseling, and reproductive pathology testing. Operating across Australia and Southeast Asia, the business manages network fertility clinics, ultrasound centers, day hospitals, and specialized diagnostic laboratories. The group actively conducts research and clinical development through its dedicated research foundation to advance reproductive medicine standards.
Snapshot
Operations
Products and/or services of Monash Ivf Group
- Assisted Reproductive Technology: Comprehensive fertility services encompassing in vitro fertilization, intracytoplasmic sperm injection, ovulation induction, and intrauterine insemination delivered through network clinics and specialized day surgery hospitals across Australia and Southeast Asia.
- Specialized Ultrasound Diagnostics: Tertiary-level obstetric and gynaecological ultrasound imaging, prenatal diagnostic testing, high-risk pregnancy monitoring, and specialized pelvic scans conducted by certified sonographers and clinical specialists in dedicated diagnostic centers.
- Pre-Implantation Genetic Testing: Advanced genetic screening and diagnostic procedures to identify chromosomal abnormalities, structural rearrangements, and single-gene inherited conditions in embryos prior to transfer during assisted reproductive treatment cycles.
- Donor and Surrogacy Programs: Integrated clinical, regulatory, and psychological support services for donor egg, sperm, and embryo treatments, along with complete gestational surrogacy management for domestic and international intended parents.
- Fertility Preservation Services: Oocyte, sperm, and ovarian tissue cryopreservation and long-term storage solutions for oncology patients undergoing gonadotoxic treatments as well as individuals electing proactive age-related fertility preservation.
- Pathology and Diagnostic Testing: Specialized endocrine and reproductive pathology services, including routine hormone testing, comprehensive semen analysis, genetic carrier screening, and serology diagnostics supporting fertility consultations and treatment cycle management.
Monash Ivf Group executive team
- Victoria Atkinson Afracma Fracs MbbsMD, CEO & Director
- Rebecca ReddenChief Operating Officer
- Richard Charles HenshawExecutive Director
- Birol AkdoganInterim Chief Financial Officer
- Deirdre Zander-FoxChief Scientific Officer
- Rebecca DeanCompany Secretary & General Counsel
- Niki Howells-SchrammChief People Officer
- Tedd FuellChief Governance & Risk Officer
- Fleur CattrallChief Medical Officer
Latest news about Monash Ivf Group
Monash IVF appoints Matt Harrington as new CFO
AustraliaMonash IVF Group books revenue of $269.5M in FY26
AustraliaMonash IVF lowers FY26 profit guidance
AustraliaMonash IVF appoints inaugural chief medical officer
AustraliaMonash IVF Group considers revised takeover offer
AustraliaMonash IVF settles lawsuit over embryo mix-ups
Australia
Recent announcements
What Monash Ivf Group (MVF) has told the market, newest first.
- Appendix 3Y
- Appendix 3X
- Appendix 3Z
- Appendix 3Z
- Appendix 3Z
- Director resignation and withdrawal of AGM resolution 3c
- Notice of 2026 AGM, Proxy Form and Access Letter
- Annual Report to shareholders
Dividend history
Dividends per share paid by Monash Ivf Group, by financial year.
| Financial year | Interim | Final | Special | Total |
|---|---|---|---|---|
| FY2026 | A$0.0120 | A$0.0130 | — | A$0.0250 |
| FY2025 | A$0.0260 | — | — | A$0.0260 |
| FY2024 | A$0.0250 | A$0.0250 | — | A$0.0500 |
| FY2023 | A$0.0220 | A$0.0220 | — | A$0.0440 |
| FY2022 | A$0.0220 | A$0.0220 | — | A$0.0440 |
Key financials
Reported results for Monash Ivf Group, in AUD.
- Market cap
- 300M
- Revenue (TTM)
- 269.5M
- P/E ratio
- 38.5
- EPS (diluted, TTM)
- 0.0
- Dividend yield
- 3.3%
- Profit margin
- 2.8%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 269.5M | 20.7M | 7.4M | |
| 271.9M | 43.4M | 25M | |
| 255M | -5.6M | -6.5M | |
| 213.6M | 33.1M | 21.8M |